Follow the origins of the immuno-oncology market in this examination of the deals and activities surrounding this important area. Such activity has resulted in a frenzy among big pharma and biotech to partner with or acquire those companies developing IO assets, making IO therapeutics the main driver in the competitive dealmaking area of oncology. Examine the deals and events from the first IO checkpoint inhibitor approvals (Merck & Co. Inc.’s Keytruda and Bristol-Myers Squibb Co.’s Opdivo, both in 2014) leading up to the present, where IO therapeutics continue to lead the competitive oncology area with emergent technologies like CAR-T therapies, and more.